Overview

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of the treatment combination of the commercially available chemotherapy drugs, docetaxel and liposomal doxorubicin, and a blood thinner Enoxaparin on pancreatic cancer. The main goal of the study is to find out if this combination chemotherapy and enoxaparin increases the number of individuals whose tumors shrink.
Phase:
Phase 2
Details
Lead Sponsor:
University of Iowa
Collaborator:
Aventis Pharmaceuticals
Treatments:
Docetaxel
Doxorubicin
Enoxaparin
Liposomal doxorubicin